Publication: Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib
Issued Date
2018-07-01
Resource Type
ISSN
18735835
01452126
01452126
Other identifier(s)
2-s2.0-85048311409
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Leukemia Research. Vol.70, (2018), 100-105
Suggested Citation
Sung Eun Lee, Soo Young Choi, Soo Hyun Kim, Saengsuree Jootar, Hyeoung Joon Kim, Sang Kyun Sohn, Joon Seong Park, Sung Hyun Kim, Dae Young Zang, Suk Joong Oh, Dong Wook Kim Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib. Leukemia Research. Vol.70, (2018), 100-105. doi:10.1016/j.leukres.2018.06.002 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/45127
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib
Other Contributor(s)
Ajou University, School of Medicine
Kyungpook National University Hospital
Chonnam National University, College of Medicine
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Dong-A University, College of Medicine
Samsung Group
Hallym University, College of Medicine
The Catholic University of Korea
Kyungpook National University Hospital
Chonnam National University, College of Medicine
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Dong-A University, College of Medicine
Samsung Group
Hallym University, College of Medicine
The Catholic University of Korea
Abstract
© 2018 Elsevier Ltd The aim of this study was to investigate the efficacy of nilotinib (NIL) versus high-dose imatinib (IM) versus sustained standard-dose IM for patients with chronic myeloid leukemia (CML) with suboptimal molecular response to first-line IM therapy. Patients with CML who achieved complete cytogenetic response (CCyR) but not major molecular response (MMR) after 18–24 months on first-line IM therapy were enrolled and divided into three treatment cohorts: NIL 800 mg/day (Cohort 1, n = 28) and IM 800 mg/day (Cohort 2, n = 28) in the RE-NICE study, and sustained IM 400 mg/day (Cohort 3, n = 52) in clinical practice. The primary efficacy variable of cumulative rate of MMR by 12 months was not different among the three cohorts. However, the cumulative incidence of MMR by 36 months was significantly higher in Cohort 1 than Cohort 3 (83.1% vs. 57.1%, P = 0.021), but there were no significant differences in Cohort 1 vs. 2 (P = 0.195) and Cohort 2 vs. 3 (P = 0.297). Different profile for adverse events was observed between NIL and high-dose IM therapy. In conclusion, our data suggested that switching to NIL may provide more effective long-term response than sustaining standard-dose IM for patients with suboptimal molecular response to first-line IM.